GlassScriptPhysician profile
Brittany Silverman
NPI 1720545239
$16,096.01
in general payments reported to CMS, 2019-2025
29 companies · $3,214 in 2025
The $3,214 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $598 · 2022: $5,346 · 2023: $3,688 · 2024: $3,250 · 2025: $3,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,780 · Consulting Fee: $598 · Education: $425 · Travel and Lodging: $349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,779.79 |
| Consulting Fee | $598.00 |
| Education | $425.40 |
| Travel and Lodging | $349.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $3,950.75 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Abbvie INC. | $2,164.23 | 2021-2025 | |
| Janssen Biotech, INC. | $1,586.38 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| E.R. Squibb & Sons, L.L.C. | $1,355.84 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $1,109.21 | 2021-2025 | |
| Ucb, INC. | $689.04 | 2022-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $575.22 | 2023-2024 | Vtama |
| Lilly USA, LLC | $556.21 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $512.90 | 2022-2025 | Otezla, Enbrel |
| Pfizer INC. | $512.68 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $464.26 | 2022-2025 | Dupixent |
| Leo Pharma INC. | $392.23 | 2021-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $334.72 | 2021-2025 | Jublia |
| Organon LLC | $315.67 | 2025 | Vtama |
| Incyte Corporation | $248.88 | 2022-2025 | Opzelura |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $244.55 | 2022-2025 | |
| Galderma Laboratories, L.P. | $208.36 | 2021-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $205.98 | 2023-2025 | Zoryve |
| Almirall LLC | $127.65 | 2022 | |
| Sanofi-Aventis U.S. LLC | $122.16 | 2021-2022 | |
| Botanix Sb INC | $92.33 | 2025 | Sofdra |
| Genentech USA, INC. | $66.10 | 2025 | Xolair |
| Mayne Pharma Commercial LLC | $58.99 | 2023-2025 | |
| Springworks Therapeutics, INC. | $57.49 | 2025 | Gomekli |
| Biofrontera INC. | $44.08 | 2025 | Ameluz |
| Epi Health, LLC | $42.33 | 2022 | |
| Celltrion USA INC. | $21.86 | 2024 | Vegzelma |
| Lnhc, INC | $21.58 | 2025 | Zelsuvmi |
| Journey Medical Corporation | $14.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.